What is the significance of elevated Apolipoprotein B (ApoB), LDL-Cholesterol, and Non-HDL Cholesterol levels in relation to cardiovascular disease risk?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Significance of Abnormal Lipid Profile Results

Your lipid profile results indicate an elevated cardiovascular disease risk profile due to multiple abnormal markers, particularly elevated apolipoprotein B, LDL particle number, and non-HDL cholesterol, which are strong predictors of atherosclerotic cardiovascular disease.

Key Abnormal Findings and Their Significance

Primary Atherogenic Risk Markers

  • Apolipoprotein B (ApoB) at 92 mg/dL (Above Range): ApoB is the major apoprotein of all atherogenic lipoproteins and has strong predictive power for severity of coronary atherosclerosis and cardiovascular events 1
  • LDL Particle Number at 1627 nmol/L (Above Range): Elevated LDL particle number indicates increased cardiovascular risk, even when LDL cholesterol is only modestly elevated 2
  • Non-HDL Cholesterol at 149 mg/dL (Above Range): Represents the total pool of atherogenic lipoproteins and is highly correlated with apoB 1

Additional Concerning Lipid Parameters

  • LDL-Cholesterol at 132 mg/dL (Above Range): Associated with increased cardiovascular risk, though less predictive than apoB or non-HDL cholesterol in many studies 3, 4
  • Lipoprotein(a) at 190 nmol/L (Above Range): Associated with increased risk of coronary heart disease and ischemic stroke 1
  • Total Cholesterol/HDL Ratio at 4.0 (Above Range): This ratio is a strong predictor of cardiovascular risk 3
  • LDL Medium at 366 nmol/L and LDL Small at 263 nmol/L (Both Above Range): Small, dense LDL particles are particularly atherogenic 1

Cardiovascular Risk Assessment

Risk Stratification

  • The combination of elevated apoB, LDL particle number, and non-HDL cholesterol significantly increases your cardiovascular risk profile 2, 5
  • ApoB has been shown to be a superior predictor of cardiovascular disease compared to LDL cholesterol in multiple studies 6, 5
  • The presence of elevated Lipoprotein(a) further increases cardiovascular risk independently of other lipid parameters 1

Comparative Marker Value

  • Non-HDL cholesterol and apoB are more potent predictors of cardiovascular disease incidence than LDL cholesterol alone, especially when triglycerides are not severely elevated (yours are normal at 73 mg/dL) 3, 4
  • The discriminatory power for prevalent cardiovascular disease is stronger for apoB (AUC 0.60) compared to non-HDL cholesterol (AUC 0.57) and LDL cholesterol (AUC 0.54) 5

Management Implications

Treatment Targets

  • For high cardiovascular risk individuals, the target for apoB should be <100 mg/dL 2
  • For LDL cholesterol, the target should be <100 mg/dL based on your risk profile 1
  • For non-HDL cholesterol, the target should be <130 mg/dL 1

Therapeutic Approach

  • Statins should be considered as first-line therapy as they effectively lower apoB-containing lipoproteins 2
  • Lifestyle modifications including weight management, reduction in dietary saturated fat intake, and regular physical exercise can help reduce apoB levels 2
  • Monitoring should include apoB or non-HDL cholesterol levels, as they provide better assessment of residual risk than LDL cholesterol alone 4, 7

Clinical Pearls and Pitfalls

  • Pitfall: Relying solely on LDL cholesterol for risk assessment may underestimate cardiovascular risk, especially when apoB and LDL particle numbers are elevated 4, 7
  • Pearl: Non-HDL cholesterol can be easily calculated (Total cholesterol minus HDL cholesterol) and provides valuable risk information beyond LDL cholesterol 1
  • Caveat: While your triglycerides are normal (73 mg/dL), the elevated apoB and LDL particle number still indicate increased cardiovascular risk that requires attention 5

Related Questions

What is the significance of elevated Apolipoprotein B (ApoB) at 1.51 g/L, high Low-Density Lipoprotein (LDL) cholesterol at 5.81 mmol/L, and increased Non-High-Density Lipoprotein Cholesterol (non-HDL-C) at 6.11 mmol/L?
Is statin (HMG-CoA reductase inhibitor) therapy indicated for a patient with a Framingham risk score of 11.2%, elevated LDL (Low-Density Lipoprotein) cholesterol, and high non-HDL (non High-Density Lipoprotein) cholesterol?
Is an apolipoprotein test warranted for a patient with a low-density lipoprotein (LDL) level of 81 mg/dL who is already on a high-intensity statin?
What is the clinical significance of a low-density lipoprotein (LDL) level of 4.42 mmol/L, a Framingham Risk Score (FRS) of 9%, and an apolipoprotein B (Apo B) level of 1.37?
Is an elevated apolipoprotein B (ApoB) level in an elderly male patient with dyslipidemia (low High-Density Lipoprotein (HDL) cholesterol, elevated Low-Density Lipoprotein (LDL) cholesterol, and elevated triglycerides) an indicator of increased risk for atherosclerotic cardiovascular disease (ASCVD)?
Can Eperisone and Celecoxib (Celebrex) be given together?
What should I prioritize for pain management?
What is the recommended vitamin D treatment for patients with end-stage kidney disease?
What antipsychotics, excluding risperidone (Risperdal) and aripiprazole (Abilify), have a low seizure threshold?
What is the recommended treatment approach for a patient with frozen shoulder?
Is medication warranted for a 27-year-old female with elevated apolipoprotein B and LDL particle number, or can lifestyle modifications alone manage her lipid parameters?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.